JNJ-31020028 ( JNJ31020028; JNJ 31020028; JNJ-31020028 )

产品货号. M10369 CAS No. 1094873-14-9

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

拼团产品询价大包装询价加入购物车

产品名称

JNJ-31020028
注意事项

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
产品简述

JNJ-31020028 is a selective brain penetrant antagonist of neuropeptide Y2 receptor with high affinity(pIC50=8.07, human; pIC50=8.22 rat).
产品描述

JNJ-31020028 is a selective brain penetrant antagonist of neuropeptide Y2 receptor with high affinity(pIC50=8.07, human; pIC50=8.22 rat); >100-fold selective versus human Y1/Y4/Y5 receptors.
同义词

JNJ31020028; JNJ 31020028; JNJ-31020028
通路

Others
靶点

Other Targets
受体

Y2 receptor
研究领域

Neurological Disease
适应症

——

CAS Number

1094873-14-9
分子量

565.68
分子式

C34H36FN5O2
纯度

>98%(HPLC)
溶解度

DMSO: 10 mM
SMILES

O=C(NC1=CC=C(N2CCN(C(C3=CC=CC=C3)C(N(CC)CC)=O)CC2)C(F)=C1)C4=CC=CC=C4C5=CC=CN=C5
化学全称

N-(4-(4-(2-(diethylamino)-2-oxo-1-phenylethyl)piperazin-1-yl)-3-fluorophenyl)-2-(pyridin-3-yl)benzamide

1.Shoblock JR, et al. Psychopharmacology (Berl). 2010 Feb;208(2):265-77.

计算器

产品手册

关联产品

VULM 1457

VULM 1457 is a potent ACAT inhibitor. VULM 1457 has remarkable hypolipidaemic activity and improves the overall myocardial ischaemia-reperfusion injury outcomes.
Linzagolix

Linzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis.
DCLK1-IN-1

DCLK1-IN-1 is a selective and in vivo-compatible chemical probe of the DCLK1 kinase domain .